Welcome to ID4Pharma
Intelligent Drug Design Discovery Development (ID4Pharma or ID4)
ID4Pharma is a University-Pittsburgh technology-based Biotech startup and is a leading innovator for new drug discovery. ID4 has developed a global patent of a first-in-class SQSTM1 target-specific anti-multiple myeloma (MM) new drug: Sequesta™. ID4 a winner of the SBIR ‘Fast Track’ grant award. ID4 Executive Management Team Members of CEO, CSO and CDO were from former Pharma companies and had rich drug R&D and FDA regulation approval experience. They are fully capable of taking the technology to next phases. ID4 has completed FDA IND-enabling preclinical trials. Now, it moves to human clinical trials with a full speed commercialization toward drug market.
ID4Pharma is a University-Pittsburgh technology-based Biotech startup and is a leading innovator for new drug discovery. ID4 has developed a global patent of a first-in-class SQSTM1 target-specific anti-multiple myeloma (MM) new drug: Sequesta™. ID4 a winner of the SBIR ‘Fast Track’ grant award. ID4 Executive Management Team Members of CEO, CSO and CDO were from former Pharma companies and had rich drug R&D and FDA regulation approval experience. They are fully capable of taking the technology to next phases. ID4 has completed FDA IND-enabling preclinical trials. Now, it moves to human clinical trials with a full speed commercialization toward drug market.
TargetHunter Intelligent Drug R&D PlatformID4Pharma has a solid expertise on R&D studies and established a Medicinal Chemistry/Biology Drug Discovery Platform integrated by "Big-data" machine/deep learning system pharmacology TargetHunter computing, bioassays, and medicinal chemistry knowledge.
Innovational Drug Discovery PatentsID4 scientists' are the inventor(s) of multiple drug discovery patents consisting from terminal illness medications to augmented and virtual reality drug design platforms used for both commercial and educational functions.
|
Breakthrough Multiple Myeloma TreatmentSequesta™ has its competitive advantage in treatment of MM disease relapse, particularly for MM patients who develop drug resistance in clinics. Another uniqueness of drug Sequesta™ is its dual therapeutics of high in vivo efficacy of inhibiting MM tumor growth and improving the tumor-bearing bone density without drug resistance observed.
Fast-track SBIR Funding AwardID4Pharma was awarded for 'fast track' SBIR grant and has completed the FDA IND-enabling preclinical studies of new drug Sequesta™, showing high efficacy and low GLP-toxicity in Rat and Monkey, and is in its stage of human clinical trials now.
|
ID4Pharma has recently received a $2.3 Million federal 'fast track' grant in order to advance the progression of our Multiple Myeloma drug to provide a new innovative treatment method. |
|
What we are looking for
We are seeking strategic partners and VCs/investors for Phase IB/IIA human clinical trials., ultimately towards to drug market. (Sean@ID4Pharma.com Cell 832-755-1268)
.
.